Project Grant K99GM163031
- The National Institute of General Medical Sciences, an operating division of the Department of Health and Human Services National Institutes of Health, awarded $456,500 to The University of Texas Southwestern Medical Center on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859). This Project Grant (R35GM162146) funds research into the structure and mechanisms of the mitochondrial pyruvate carrier (MPC), a protein essential for transporting pyruvate into...
- The National Institute of General Medical Sciences awarded the University of Utah $885,637 in project grant funding on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859). The University of Utah, through its Office of Sponsored Projects Division, will conduct a five-year investigation into the molecular and metabolic adaptations that enable apicomplexan parasites—particularly Plasmodium species that cause malaria—to survive and replicate within host cells....
- The National Heart Lung and Blood Institute awarded the University of Utah $367,200 on September 19, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate metabolite transport modulation in myocardial ischemic-reperfusion injury. The research focuses on inhibition of monocarboxylate transporter 4 (MCT4), which regulates lactate excretion from cardiomyocytes, as a potential cardioprotective intervention following heart attack. The project comprises four specific...
- The National Institute of General Medical Sciences awarded New York University $125,000 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support a K99/R00 project investigating mitonuclear regulation in Caenorhabditis elegans. The research aims to determine how interactions between mitochondrial and nuclear genomes regulate gene expression and stress responses across tissues. Using natural mitochondrial variation in C. elegans combined with...
- The National Institute of General Medical Sciences, operating as part of the Department of Health and Human Services National Institutes of Health, awarded the University of Utah $423,500 on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859). The award funds research investigating the biological functions, biosynthesis, and dynamic regulations of RNA chemical modifications. The research program addresses three key challenges: identifying proteins that...
- The National Heart, Lung, and Blood Institute awarded the University of Utah $248,999 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for basic research into WNK1-dependent macropinocytosis and emergency myelopoiesis. The project investigates how the chloride-sensing kinase WNK1 regulates myeloid progenitor cell fate, particularly the shift from monocyte/macrophage lineage commitment toward emergency granulopoiesis during systemic infection. Research...
- The National Institute of General Medical Sciences awarded the University of California, San Diego $440,000 on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to conduct research on membrane-protein interactions that control mitochondrial shape and function. The research develops multiscale biophysical tools and computer simulations to integrate molecular details into models of large-scale membrane bending in mitochondria. The work addresses two problem...
- The National Institute of General Medical Sciences, part of the National Institutes of Health within the Department of Health and Human Services, awarded The University of Texas Southwestern Medical Center $488,525 on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859), a Project Grant (R35GM162011). The award funds evolution-guided studies of mitochondrial activities and the host response to infectious agents. The research characterizes newly identified...
- The National Institute of General Medical Sciences awarded $422,688 to the Regents of the University of California at Riverside on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859, Assistance Listing 93.859). The award funds basic research on cell signaling through the primary cilium, a microtubule-based organelle that functions as the cell's signaling hub. The research addresses how the primary cilium senses environmental signaling cues and transduces...
- The National Institute of General Medical Sciences awarded the University of Utah $392,942 on May 22, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support research on the regulation of single-cell migration in vivo. The award funds investigation into how focal adhesion structures form and function during cell migration in living organisms, specifically using zebrafish larval skin as a model system to directly visualize focal adhesion dynamics in highly...
The National Institute of General Medical Sciences awarded the University of Utah $125,000 on August 14, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support research elucidating the role of Wnt/beta-catenin signaling in mitochondrial metabolism and cell behavior. The project investigates the molecular mechanisms by which beta-catenin and its downstream target gene c-myc regulate expression of the mitochondrial pyruvate carrier (MPC1 and MPC2), transmembrane proteins that facilitate pyruvate entry into mitochondria for metabolic reactions including the TCA cycle. Preliminary findings demonstrate that beta-catenin suppresses MPC gene expression; treatment with GSK3 inhibitors, which activate Wnt/beta-catenin signaling, reduced MPC1 and MPC2 mRNA and protein expression. The investigator has shown that c-myc overexpression decreases MPC1 expression in human dermal fibroblasts, whereas c-myc knockdown increases it. The funded research will define the mechanisms of this regulation and assess its significance in cell metabolism and proliferation, with implications for understanding metabolic deregulation in diabetes, cancer, and neurodegenerative diseases. Performance occurs in Salt Lake City, Utah, with a period of performance from the award date through July 31, 2028. This is a K99/R00 postdoctoral transition award, a Project Grant assistance type supporting investigator-initiated research through the National Institutes of Health.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $125.0k | 8/14/26 |